Literature DB >> 19840578

Six-month follow-up of patients with in-hospital thrombocytopenia during heparin-based anticoagulation (from the Complications After Thrombocytopenia Caused by Heparin [CATCH] registry).

Renato D Lopes1, E Magnus Ohman, Christopher B Granger, Emily F Honeycutt, Kevin J Anstrom, Peter B Berger, Eric M Crespo, Gustavo B F Oliveira, Stephan Moll, David J Moliterno, Charles S Abrams, Richard C Becker.   

Abstract

Thrombocytopenia is a predictor of adverse outcomes in patients with acute coronary syndromes and in critically ill patients. The Complications After Thrombocytopenia Caused by Heparin (CATCH) registry was designed to explore the incidence, management, and clinical consequences of in-hospital thrombocytopenia occurring during heparin-based anticoagulation in diverse clinical settings. We conducted a prospective observational study of 37 United States hospitals participating in the CATCH registry to assess the relation of in-hospital thrombocytopenia to long-term outcomes. A total of 2,104 patients at increased risk of developing in-hospital thrombocytopenia or thrombosis were identified, and the 6-month mortality and rehospitalization rates were determined. Thrombocytopenia was not a significant predictor of 6-month mortality. In an adjusted model for in-hospital death in this cohort, thrombocytopenia had an odds ratio of 3.59 (95% confidence interval 2.24 to 5.77). The postdischarge mortality rate at 6 months was 9.7%. No significant difference was observed in the long-term mortality between patients who developed thrombocytopenia and those who did not. Thrombocytopenia was a weak, but statistically significant, predictor of a composite of mortality and rehospitalization at 6 months (hazards ratio 0.80, 95% confidence interval 0.65 to 0.98, p = 0.03). In conclusion, the 6-month mortality rate among heparin-treated patients with thrombocytopenia is high, although the risk independently related to thrombocytopenia appears to be restricted to the acute hospital phase.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19840578     DOI: 10.1016/j.amjcard.2009.06.045

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  3 in total

1.  Highlights from the II International Symposium of Thrombosis and Anticoagulation (ISTA), October 22-23, 2009, São Paulo, Brazil.

Authors:  Renato D Lopes; David Garcia; Richard C Becker; Christopher B Granger; L Kristin Newby; John H Alexander; E Marc Jolicoeur; Allison Handler; Karen S Pieper; Antonio C Carvalho; Helio P Guimaraes; Dalton A F Chamone; Antonio C Baruzzi; Fabio S Machado; Ari Timerman; Antonio C Lopes
Journal:  J Thromb Thrombolysis       Date:  2010-05       Impact factor: 2.300

Review 2.  Antithrombotic therapy in heparin-induced thrombocytopenia: guidelines translated for the clinician.

Authors:  Connie N Hess; Richard C Becker; John H Alexander; Renato D Lopes
Journal:  J Thromb Thrombolysis       Date:  2012-11       Impact factor: 2.300

3.  A preliminary randomised controlled study of short-term Antrodia cinnamomea treatment combined with chemotherapy for patients with advanced cancer.

Authors:  Ming-Yen Tsai; Yu-Chiang Hung; Yen-Hao Chen; Yung-Hsiang Chen; Yu-Chuen Huang; Chao-Wei Kao; Yu-Li Su; Hsien-Hsueh Elley Chiu; Kun-Ming Rau
Journal:  BMC Complement Altern Med       Date:  2016-08-26       Impact factor: 3.659

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.